More Increlex Coming Soon

Ipsen announced that in collaboration with the Food and Drug Administration (FDA), it is releasing an additional batch of Increlex (mecasermin [rDNA origin]).

Interruption in Increlex supply occurred in mid-June 2013 due to manufacturing issues. Since then, the first batch of Increlex was made available for distribution in June of 2014.The additional batch of Increlex will be available starting in November 2015.

RELATED: Ipsen Continues to Resupply Increlex

Increlex is a recombinant human insulin-like growth factor-1 (rhIGF-1) indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency (IGFD), or in those with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

For more information call (866) 837-2422 or visit